Literature DB >> 28592886

MDS with deletions in the long arm of chromosome 11 are associated with a high frequency of SF3B1 mutations.

A Stengel1, W Kern1, M Meggendorfer1, T Haferlach1, C Haferlach1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28592886     DOI： 10.1038/leu.2017.180

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  15 in total

1.  Comparison of chromosome banding analysis, interphase- and hypermetaphase-FISH, qualitative and quantitative PCR for diagnosis and for follow-up in chronic myeloid leukemia: a study on 350 cases.

Authors:  C Schoch; S Schnittger; S Bursch; D Gerstner; A Hochhaus; U Berger; R Hehlmann; W Hiddemann; T Haferlach
Journal:  Leukemia       Date:  2002-01       Impact factor: 11.528

Review 2.  Unraveling the molecular pathophysiology of myelodysplastic syndromes.

Authors:  Rafael Bejar; Ross Levine; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2011-01-10       Impact factor: 44.544

3.  Myelodysplastic syndromes with deletions of chromosome 11q lack cryptic MLL rearrangement and exhibit characteristic clinicopathologic features.

Authors:  Sa A Wang; Lynne V Abruzzo; Robert P Hasserjian; Liping Zhang; Ying Hu; Yanpeng Zhang; Ming Zhao; Naomi Galili; Azar Raza; L Jeffrey Medeiros; Guillermo Garcia-Manero; Roberto N Miranda
Journal:  Leuk Res       Date:  2010-08-05       Impact factor: 3.156

Review 4.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

Authors:  Daniel A Arber; Attilio Orazi; Robert Hasserjian; Jürgen Thiele; Michael J Borowitz; Michelle M Le Beau; Clara D Bloomfield; Mario Cazzola; James W Vardiman
Journal:  Blood       Date:  2016-04-11       Impact factor: 22.113

5.  New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients.

Authors:  Detlef Haase; Ulrich Germing; Julie Schanz; Michael Pfeilstöcker; Thomas Nösslinger; Barbara Hildebrandt; Andrea Kundgen; Michael Lübbert; Regina Kunzmann; Aristoteles A N Giagounidis; Carlo Aul; Lorenz Trümper; Otto Krieger; Reinhard Stauder; Thomas H Müller; Friedrich Wimazal; Peter Valent; Christa Fonatsch; Christian Steidl
Journal:  Blood       Date:  2007-08-28       Impact factor: 22.113

6.  New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge.

Authors:  Julie Schanz; Heinz Tüchler; Francesc Solé; Mar Mallo; Elisa Luño; José Cervera; Isabel Granada; Barbara Hildebrandt; Marilyn L Slovak; Kazuma Ohyashiki; Christian Steidl; Christa Fonatsch; Michael Pfeilstöcker; Thomas Nösslinger; Peter Valent; Aristoteles Giagounidis; Carlo Aul; Michael Lübbert; Reinhard Stauder; Otto Krieger; Guillermo Garcia-Manero; Stefan Faderl; Sherry Pierce; Michelle M Le Beau; John M Bennett; Peter Greenberg; Ulrich Germing; Detlef Haase
Journal:  J Clin Oncol       Date:  2012-02-13       Impact factor: 44.544

7.  Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes.

Authors:  Rafael Bejar; Kristen E Stevenson; Bennett A Caughey; Omar Abdel-Wahab; David P Steensma; Naomi Galili; Azra Raza; Hagop Kantarjian; Ross L Levine; Donna Neuberg; Guillermo Garcia-Manero; Benjamin L Ebert
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

8.  Distribution of cytogenetic abnormalities in myelodysplastic syndromes, Philadelphia negative myeloproliferative neoplasms, and the overlap MDS/MPN category.

Authors:  Ulrike Bacher; Susanne Schnittger; Wolfgang Kern; Tamara Weiss; Torsten Haferlach; Claudia Haferlach
Journal:  Ann Hematol       Date:  2009-05-05       Impact factor: 3.673

9.  Clinical and biological implications of driver mutations in myelodysplastic syndromes.

Authors:  Elli Papaemmanuil; Moritz Gerstung; Luca Malcovati; Sudhir Tauro; Gunes Gundem; Peter Van Loo; Chris J Yoon; Peter Ellis; David C Wedge; Andrea Pellagatti; Adam Shlien; Michael John Groves; Simon A Forbes; Keiran Raine; Jon Hinton; Laura J Mudie; Stuart McLaren; Claire Hardy; Calli Latimer; Matteo G Della Porta; Sarah O'Meara; Ilaria Ambaglio; Anna Galli; Adam P Butler; Gunilla Walldin; Jon W Teague; Lynn Quek; Alex Sternberg; Carlo Gambacorti-Passerini; Nicholas C P Cross; Anthony R Green; Jacqueline Boultwood; Paresh Vyas; Eva Hellstrom-Lindberg; David Bowen; Mario Cazzola; Michael R Stratton; Peter J Campbell
Journal:  Blood       Date:  2013-09-12       Impact factor: 22.113

10.  Landscape of genetic lesions in 944 patients with myelodysplastic syndromes.

Authors:  T Haferlach; Y Nagata; V Grossmann; Y Okuno; U Bacher; G Nagae; S Schnittger; M Sanada; A Kon; T Alpermann; K Yoshida; A Roller; N Nadarajah; Y Shiraishi; Y Shiozawa; K Chiba; H Tanaka; H P Koeffler; H-U Klein; M Dugas; H Aburatani; A Kohlmann; S Miyano; C Haferlach; W Kern; S Ogawa
Journal:  Leukemia       Date:  2013-11-13       Impact factor: 11.528
View more
  3 in total

1.  Impact of splicing factor mutations on clinical features in patients with myelodysplastic syndromes.

Authors:  Naoki Shingai; Yuka Harada; Hiroko Iizuka; Yosuke Ogata; Noriko Doki; Kazuteru Ohashi; Masao Hagihara; Norio Komatsu; Hironori Harada
Journal:  Int J Hematol       Date:  2018-10-23       Impact factor: 2.490

2.  The CADM1 tumor suppressor gene is a major candidate gene in MDS with deletion of the long arm of chromosome 11.

Authors:  Marina Lafage-Pochitaloff; Bastien Gerby; Véronique Baccini; Laetitia Largeaud; Vincent Fregona; Naïs Prade; Pierre-Yves Juvin; Laura Jamrog; Pierre Bories; Sylvie Hébrard; Stéphanie Lagarde; Véronique Mansat-De Mas; Oliver M Dovey; Kosuke Yusa; George S Vassiliou; Joop H Jansen; Tobias Tekath; David Rombaut; Geneviève Ameye; Carole Barin; Audrey Bidet; John Boudjarane; Marie-Agnès Collonge-Rame; Carine Gervais; Antoine Ittel; Christine Lefebvre; Isabelle Luquet; Lucienne Michaux; Nathalie Nadal; Hélène A Poirel; Isabelle Radford-Weiss; Bénédicte Ribourtout; Steven Richebourg; Stéphanie Struski; Christine Terré; Isabelle Tigaud; Dominique Penther; Virginie Eclache; Michaela Fontenay; Cyril Broccardo; Eric Delabesse
Journal:  Blood Adv       Date:  2022-01-25

3.  Mutations and karyotype in myelodysplastic syndromes: TP53 clusters with monosomal karyotype, RUNX1 with trisomy 21, and SF3B1 with inv(3)(q21q26.2) and del(11q).

Authors:  Ayalew Tefferi; Dame Idossa; Terra L Lasho; Mythri Mudireddy; Christy Finke; Sahrish Shah; Maura Nicolosi; Mrinal M Patnaik; Animesh Pardanani; Naseema Gangat; Curt A Hanson; Rhett P Ketterling
Journal:  Blood Cancer J       Date:  2017-12-18       Impact factor: 11.037
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.